BioconKiran Mazumdar-ShawSuccession PlanningBiotechnologyCorporate Restructuring
Biocon Announces Five-Year Succession Plan, Merges Biologics and Generics Units
Published: May 10, 2026
Loading article...
Loading article...
Biocon founder and chairperson Kiran Mazumdar-Shaw has announced a five-year succession plan that will see her niece, Claire Mazumdar, eventually assume leadership of the company, marking a significant generational shift for the Bengaluru-based biotech firm she founded in 1978. Concurrently, Biocon is merging its generics and biosimilars businesses into a unified global biopharma platform by March 31, 2026, to streamline operations and accelerate growth in diabetes, oncology, and immunology markets.
Claire Mazumdar, 37, currently serves as founding CEO of Bicara Therapeutics, a Nasdaq-listed biotech firm incubated by Biocon, and holds a PhD in cancer biology from Stanford University. She is the daughter of Kiran Mazumdar-Shaw’s brother, Ravi Mazumdar. As part of the transition, Shreehas Tambe was appointed CEO and Managing Director of Biocon in April 2026 to strengthen executive leadership during the handover period.
The restructuring aims to consolidate Biocon Biologics into the parent company and sharpen focus on biologics, cancer therapeutics, immunotherapy, and affordable insulin. The move positions Biocon to strengthen its global presence in biosimilars, with over 30 biosimilar products developed and 12 commercially launched across the U.S., Europe, and other markets.
Under Mazumdar-Shaw’s leadership, Biocon evolved from a garage-scale enzyme manufacturer into India’s leading biotechnology company and a major player in the global biosimilars market. Her advocacy helped establish Bengaluru as a biotech hub, with Karnataka’s bioeconomy reaching $39.2 billion in March 2026, contributing over 10% to the state’s GSDP.
The company will continue executing the integration of its biopharma businesses, with the court-supervised merger process and leadership development expected to conclude by 2031, according to company statements.